These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6828553)

  • 1. High-dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia.
    Rimón R; Terenius L; Averbuch I; Belmaker RH
    Pharmacopsychiatria; 1983 Jan; 16(1):9-12. PubMed ID: 6828553
    [No Abstract]   [Full Text] [Related]  

  • 2. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
    Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP
    Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects.
    Dalal MA; Schuld A; Pollmächer T
    Mol Psychiatry; 2003 Oct; 8(10):836-7. PubMed ID: 14515133
    [No Abstract]   [Full Text] [Related]  

  • 7. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
    van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E
    Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia.
    Weston MJ; Bentley R; Unwin A; Morris M; Harper MA
    Aust N Z J Psychiatry; 1973 Mar; 7(1):52-7. PubMed ID: 4579393
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebrospinal fluid endorphins in schizophrenia.
    Rimón R; Terenius L; Kampman R
    Acta Psychiatr Scand; 1980 May; 61(5):395-403. PubMed ID: 7405608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C.S.F. beta-endorphin in schizophrenia.
    Domschke W; Dickschas A; Mitznegg P
    Lancet; 1979 May; 1(8124):1024. PubMed ID: 86731
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of haloperidol in a "hard-core" chronic schizophrenic population.
    Lee H
    Psychosomatics; 1968; 9(5):267-71. PubMed ID: 4879677
    [No Abstract]   [Full Text] [Related]  

  • 12. Somatostatin-like immunoreactivity in CSF in schizophrenic patients during haloperidol treatment.
    Jolkkonen J; Pitkänen A; Riekkinen PJ; Korpi ER; Kaufmann CA; Weinberger DR
    Biol Psychiatry; 1992 May; 31(9):962-4. PubMed ID: 1637934
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical efficacy of haloperidol in chronic psychotic patients.
    Lapolla A
    Int J Neuropsychiatry; 1967 Aug; 3():Suppl l:68-77. PubMed ID: 6051725
    [No Abstract]   [Full Text] [Related]  

  • 14. [Beta-endorphin concentration in the cerebrospinal fluid of schizophrenics].
    Ignatov SA; Burbaeva GSh; Tsutsul'kovskaia MIa; Abramova LI; Trubnikov VI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(9):1331-7. PubMed ID: 6108032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid inactivation of enkephalin-like material by C.S.F. in chronic schizophrenia.
    Dupont A; Villeneuve A; Bouchard JP; Bouchard R; Mérand Y; Rouleau D; Labrie F
    Lancet; 1978 Nov; 2(8099):1107. PubMed ID: 82132
    [No Abstract]   [Full Text] [Related]  

  • 16. [Norepinephrine turnover under neuroleptic treatment of schizophrenic syndromes (author's transl)].
    Eben E; Ackenheil M; Rüther E
    Arzneimittelforschung; 1978; 28(9):1498. PubMed ID: 38809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.
    Gerlach J; Koppelhus P; Helweg E; Monrad A
    Acta Psychiatr Scand; 1974; 50(4):410-24. PubMed ID: 4153596
    [No Abstract]   [Full Text] [Related]  

  • 18. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
    McAllister CG; van Kammen DP; Rehn TJ; Miller AL; Gurklis J; Kelley ME; Yao J; Peters JL
    Am J Psychiatry; 1995 Sep; 152(9):1291-7. PubMed ID: 7653683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
    Gerlach J; Thorsen K; Fog R
    Psychopharmacologia; 1975; 40(4):341-50. PubMed ID: 1096218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics.
    Hall WB; Vestre ND; Schiele BC; Zimmermann R
    Dis Nerv Syst; 1968 Jun; 29(6):405-8. PubMed ID: 4877748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.